Dirk J Blom

List of Publications by Year
in descending order

76 papers	8,636 citations	126907 33 h-index	74163 75 g-index
76 all docs	76 docs citations	76 times ranked	7343 citing authors

#	Article	IF	Citations
1	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, The, 2022, 399, 719-728.	13.7	69
2	A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting. Advances in Therapy, 2022, 39, 1857-1870.	2.9	7
3	Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E Isoforms. Current Atherosclerosis Reports, 2022, , 1.	4.8	2
4	Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clinical Infectious Diseases, 2021, 73, e2005-e2015.	5.8	405
5	Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 934-943.	2.4	5
6	COVID-19â€“Associated Graft Loss From Renal Infarction in a Kidney Transplant Recipient. Kidney International Reports, 2021, 6, 1166-1169.	0.8	9
7	Lipoprotein metabolism in familial hypercholesterolemia. Journal of Lipid Research, 2021, 62, 100062.	4.2	31
8	Protocol for systematic review and meta-analysis: impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases. BMJ Open, 2020, 10, e039034.	1.9	1
9	Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER). Journal of Clinical Lipidology, 2020, 14, 807-817.	1.5	41
10	Homozygous familial hypercholesterolemia and its treatment by inclisiran. Expert Opinion on Orphan Drugs, 2020, 8, 197-208.	0.8	1
11	Efficacy and Safety of Alirocumab inÂAdults With Homozygous FamilialÂHypercholesterolemia. Journal of the American College of Cardiology, 2020, 76, 131-142.	2.8	96
12	Long-Term Evolocumab in Patients With FamilialÂHypercholesterolemia. Journal of the American College of Cardiology, 2020, 75, 565-574.	2.8	126
13	Effects of evolocumab therapy and low LDLâ€€ levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes. Endocrinology, Diabetes and Metabolism, 2020, 3, e00123.	2.4	7
14	PCSK9 Inhibitors: From Natureâ€™s Lessons to Clinical Utility. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 840-854.	1.2	6
15	Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. New England Journal of Medicine, 2019, 381, 531-542.	27.0	359
16	Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia. JACC Basic To Translational Science, 2019, 4, 425-427.	4.1	5
17	Low-density lipoprotein cholesterol goal achievement in patients with familial hypercholesterolemia in countries outside Western Europe: The International ChoLesterol management Practice Study. Journal of Clinical Lipidology, 2019, 13, 594-600.	1.5	17
18	Lomitapide and Mipomersenâ€”Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. Current Atherosclerosis Reports, 2019, 21, 48.	4.8	36

#	Article	IF	Citations
19	Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS). Cardiovascular Journal of Africa, 2019, 30, 15-23.	0.4	9
20	Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study. Cardiovascular Journal of Africa, 2019, 30, 279-284.	0.4	2
21	A Pharmacogenetic Approach to the Treatment of Patients With PPARG Mutations. Diabetes, 2018, 67, 1086-1092.	0.6	30
22	Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor). Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 592-598.	2.4	77
23	LONG-TERM SAFETY AND EFFICACY OF LOMITAPIDE IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: THREE-YEAR DATA FROM THE LOMITAPIDE OBSERVATIONAL WORLDWIDE EVALUATION REGISTRY (LOWER). Journal of the American College of Cardiology, 2018, 71, A168.	2.8	4
24	Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. European Heart Journal, 2018, 39, 1162-1168.	2.2	81
25	Effect of Evolocumab on Lipoprotein Particles. American Journal of Cardiology, 2018, 121, 308-314.	1.6	29
26	Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice. Atherosclerosis, 2018, 277, 470-476.	0.8	6
27	Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. Atherosclerosis, 2018, 277, 502-507.	0.8	37
28	LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C. Atherosclerosis, 2018, 277, 327-333.	0.8	12
29	Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). European Journal of Preventive Cardiology, 2018, 25, 1087-1094.	1.8	86
30	Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia. Orphanet Journal of Rare Diseases, 2018, 13, 96.	2.7	31
31	Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study. Journal of Clinical Lipidology, 2018, 12, 1234-1243.e5.	1.5	40
32	Therapeutic Management of Dyslipidemia Patients at Very High Cardiovascular Risk (CARDIO TRACK): Protocol for the Observational Registry Study. JMIR Research Protocols, 2018, 7, e163.	1.0	1
33	Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes and Endocrinology,the, 2017, 5, 280-290.	11.4	191
34	Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia. New England Journal of Medicine, 2017, 376, 1647-1658.	27.0	112
35	Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Circulation, 2017, 136, 332-335.	1.6	103
36	Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). American Journal of Cardiology, 2017, 120, 931-939.	1.6	25

#	Article	IF	Citations
37	Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. American Journal of Cardiology, 2017, 120, 1521-1527.	1.6	36
38	Impact of Targetâ€Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). Journal of Clinical Pharmacology, 2017, 57, 616-626.	2.0	32
39	Evaluation of the efficacy, safety and glycaemic effects of evolocumab (<scp>AMG</scp> 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes, Obesity and Metabolism, 2017, 19, 98-107.	4.4	60
40	World Heart Federation Cholesterol Roadmap. Global Heart, 2017, 12, 179.	2.3	30
41	PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Vascular Health and Risk Management, 2016, 12, 185.	2.3	16
42	Anti-Retroviral Therapy Increases the Prevalence of Dyslipidemia in South African HIV-Infected Patients. PLoS ONE, 2016, 11, e0151911.	2.5	38
43	Evolocumab for the treatment of homozygous familial hypercholesterolaemia. Expert Opinion on Orphan Drugs, 2016, 4, 789-798.	0.8	3
44	Acute Pancreatitis is Highly Prevalent and Complications can be Fatal in Patients with Familial Chylomicronemia: Results From a Survey of Lipidologist. Journal of Clinical Lipidology, 2016, 10, 680-681.	1.5	25
45	PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. Journal of Lipid Research, 2016, 57, 1086-1096.	4.2	180
46	Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemiaâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1647-1650.	2.4	23
47	PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) ExÂVivo. JACC Basic To Translational Science, 2016, 1, 419-427.	4.1	94
48	LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design. Journal of Clinical Lipidology, 2016, 10, 273-282.	1.5	35
49	Anacetrapib in familial hypercholesterolaemia: pros and cons. Lancet, The, 2015, 385, 2124-2126.	13.7	4
50	Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. European Heart Journal, 2015, 36, 1186-1194.	2.2	344
51	Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine, 2015, 372, 1500-1509.	27.0	1,352
52	Effects of Evolocumab on Vitamin E and Steroid Hormone Levels. Circulation Research, 2015, 117, 731-741.	4.5	80
53	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. European Heart Journal, 2015, 36, ehv370.	2.2	395
54	Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 385, 341-350.	13.7	609

#	Article	IF	Citations
55	Abstract 12450: Long-Term Efficacy and Safety of Lomitapide for the Treatment of Homozygous Familial Hypercholesterolemia: Results of the Phase 3 Extension Trial. Circulation, 2015, 132, .	1.6	3
56	Evolocumab in Hyperlipidemia. New England Journal of Medicine, 2014, 371, 876-878.	27.0	7
57	Normalization of Low-Density Lipoprotein Receptor Expression inÂReceptor Defective Homozygous Familial Hypercholesterolemia byÂInhibition of PCSK9 With Alirocumab. Journal of the American College of Cardiology, 2014, 64, 2299-2300.	2.8	30
58	Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovascular Disorders, 2014, 14, 121.	1.7	48
59	Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects. Journal of the American College of Cardiology, 2014, 63, 2365-2373.	2.8	57
60	Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145). Journal of the American College of Cardiology, 2014, 63, 1278-1288.	2.8	316
61	A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. New England Journal of Medicine, 2014, 370, 1809-1819.	27.0	607
62	Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. Atherosclerosis Supplements, 2014, 15, 33-45.	1.2	27
63	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet, The, 2013, 381, 40-46.	13.7	624
64	Recent advances in the treatment of homozygous familial hypercholesterolaemia. Current Opinion in Lipidology, 2013, 24, 288-294.	2.7	20
65	The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol. Clinical Lipidology, 2013, 8, 243-256.	0.4	2
66	Prevalence of dyslipidaemia in statin-treated patients in South Africa : results of the DYSlipidaemia International Study (DYSIS). Cardiovascular Journal of Africa, 2013, 24, 330-338.	0.4	16
67	Proprotein convertase subtilisin/kexin type 9 inhibition. Current Opinion in Lipidology, 2012, 23, 511-517.	2.7	38
68	Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy. Circulation, 2011, 124, 2202-2207.	1.6	301
69	LASSA Congress, Bloemfontein, April 2011. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2011, 16, 7-7.	0.2	0
70	CEPHEUS SA : a South African survey on the undertreatment of hypercholesterolaemia : cardiovascular topics. Cardiovascular Journal of Africa, 2011, 22, 234-240.	0.4	16
71	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2010, 375, 998-1006.	13.7	813
72	Rosuvastatin reduces nonâ€“high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia). Journal of Clinical Lipidology, 2008, 2, 418-425.	1.5	7

#	Article	IF	Citations
73	Non-DNA binding, dominant-negative, human PPARÎ³ mutations cause lipodystrophic insulin resistance. Cell Metabolism, 2006, 4, 303-311.	16.2	164
74	Screening for Dysbetalipoproteinemia by Plasma Cholesterol and Apolipoprotein B Concentrations. Clinical Chemistry, 2005, 51, 904-907.	3.2	45
75	Severe hypertriglyceridemia in a patient with lupus. American Journal of Medicine, 2005, 118, 443-444.	1.5	9
76	Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia. Journal of Lipid Research, 2003, 44, 212-217.	4.2	31